|
|
News Breaks
|
November 21, 2011
|
| 08:01 EDT |  | CLDX |
| theflyonthewall.com: | Celldex reports mature OS data for ACT III | | Celldex Therapeutics announced the presentation of mature overall survival data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut, or CDX-110, in patients with newly diagnosed EGFRvIII-positive glioblastoma. The data showed a final median OS of 24.6 months from diagnosis, which is significantly better than 15.2 months for a historical cohort of patients selected to match ACT III eligibility criteria. The median OS data obtained from the 31 centers participating in the ACT III study are very consistent with two previous smaller studies with rindopepimut in GB conducted at M.D. Anderson and Duke University which showed 24.6 and 24.4 month median OS, respectively. These data were described in an oral presentation at the 16th Annual Meeting of The Society for Neuro-Oncology in Orange County, CA by the lead investigator on the study, Dr. Rose Lai. :theflyonthewall.com |
|
|
News For CLDX From The Last 14 Days Check below for free stories on CLDX the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 09:13 EDT |  | CLDX |
| | 09:00 EDT | | CLDX |
| | 07:52 EDT |  | CLDX |
| theflyonthewall.com: | Celldex data not negative, says Oppenheimer | | Oppenheimer believes that data released by Celldex showed that the company's CDX-011 drug benefited patients with a large amount of cancerous cells, as it's designed to do. The firm doesn't view the lack of response in other patients as negative for the company and it maintains a $6 target and Outperform rating on the stock. :theflyonthewall.com |
|
|
May 23, 2012
|
| 16:03 EDT | | CLDX |
| theflyonthewall.com: | Celldex's CDX-011 demonstrates high response rates in patients | | Celldex Therapeutics announced preliminary results from the company's randomized Phase 2b EMERGE study of CDX-011 antibody drug conjugate in patients with glycoprotein NMB expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression. In this high expressing patient population, treatment with CDX-011 resulted in a 32% overall response rate, whereas treatment with Investigator's Choice single-agent chemotherapy resulted in a 13% ORR. CDX-011 also demonstrated strong response rates in patients with triple negative breast cancer across all levels of GPNMB expression, where treatment options are extremely limited. In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed. The ORR across all levels of GPNMB expression was 19% for the CDX-011 arm and 14% for the IC arm, and a direct, positive correlation was observed between increasing levels of GPNMB expression and increased CDX-011 response rates. Based on these data, the Company believes CDX-011 has significant promise as a targeted therapy for patients with breast cancer and high expression of GPNMB, and especially for those with triple negative disease. :theflyonthewall.com |
|
|
May 21, 2012
|
| 12:03 EDT |  | CLDX |
| theflyonthewall.com: | Celldex volatility elevated into topline results of the Phase 2b EMERGE study |
 Subscribe for More Information :theflyonthewall.com |
|
|
May 18, 2012
|
| 10:39 EDT |  | CLDX |
| theflyonthewall.com: | Celldex to host conference call | | Conference call to discuss topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be held on May 23 at 4:30 pm. Webcast Link :theflyonthewall.com |
|
|
|
|
|
